Recent Company News

• 04:43 AM ET Aug 19, 2025
  

  Sino Biopharmaceutical receives NMPA's BTD process for LM-302 for first-line therapy for gastric and gastroesophageal junction adenocarcinoma (HK$7.39, 0.00)

• 02:17 AM ET Aug 19, 2025
  

  Street Takeaways - Sino Biopharmaceutical H1 earnings (HK$7.37, -0.54)

• 10:55 PM ET Aug 18, 2025
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 05:02 AM ET Aug 18, 2025
  

  StreetAccount Metrics Recap - Sino Biopharmaceutical H1 Earnings (HK$7.91, 0.00)

• 04:45 AM ET Aug 18, 2025
  

  Sino Biopharmaceutical reports H1 net income attributable (cont. ops) CNY3.39B vs StreetAccount CNY2.29B (HK$7.91, 0.00)

• 03:31 AM ET Aug 18, 2025
  

  StreetAccount Summary: Hong Kong Stocks reaching new 52-week highs/lows (54 total)

• 12:23 AM ET Aug 18, 2025
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (170 total)

• 09:17 PM ET Aug 17, 2025
  

  Sino Biopharmaceutical initiated overweight at Industrial Securities (15-Aug, timing uncertain) (HK$7.82, 0.00)

• 03:44 AM ET Aug 15, 2025
  

  StreetAccount Summary: Hong Kong Stocks reaching new 52-week highs/lows (37 total)

• 11:24 PM ET Aug 14, 2025
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (166 total)